Hyderabad-based Hetero and the Russian Direct Investment Fund (RDIF) are aiming to start production of Sputnik V in India at the beginning of 2021. (Reuters image)Coronavirus vaccine in India: Russia has agreed to start production of its Covid-19 vaccine candidate Sputnik V in India, Sputnik V has announced on Twitter. An agreement has been reached between Russia’s sovereign wealth fund and Indian pharmaceutical company Hetero Drugs. More than 100 million (10 crore) doses of Sputnik V vaccine against Covid-19 will be produced annually, as per a Reuters report.
Hyderabad-based Hetero and the Russian Direct Investment Fund (RDIF) are aiming to start production of Sputnik V in India at the beginning of 2021. Notably, RDIF has been backing the Sputnik vaccine and marketing it globally.
Meanwhile, Phase 2 and Phase 3 human trials of Sputnik V are already going on in India, the statement on the Sputnik V Twitter account said. Drugmaker Dr. Reddy’s Laboratories Ltd has said it was expecting phase 3 clinical trials to be completed by as early as March 2021.
Earlier in November, the Russian Direct Investment Fund claimed that the Sputnik V vaccine is 92 per cent effective at protecting people from COVID-19 according to interim trial results, the Reuters report said.
Russia also said it was aiming to produce primarily freeze-dried Sputnik V coronavirus vaccine doses by the spring, a top official said, eliminating the need for transport at ultra-low temperatures as part of an ambitious plan to inoculate its population. Russia has been testing a version that has undergone lyophilisation, turning the liquid vaccine into a dry, white mass that can be stored at normal fridge temperatures of 2 to 8 degrees Celsius (35.6-46.4°F). It is then diluted before injection.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.